News | Antiplatelet and Anticoagulation Therapies | May 09, 2016

Dementia Risk Increased for Afib Patients on Long-Term Warfarin Treatment

Study of more than 10,000 patients treated with warfarin long-term reveals higher rates of dementia for AF patients versus non-AF patients

warfarin, atrial fibrillation, dementia, Intermountain Healthcare Study, HRS 2016

May 9, 2016 — A new study has found an increased risk of dementia in patients with atrial fibrillation (AF) that receive long-term blood thinner warfarin (Coumadin) compared to patients that use warfarin for conditions other than AF. The study of more than 10,000 patients treated with warfarin long-term found that patients with AF experience higher rates of dementia, Alzheimer’s disease and vascular dementia compared to anticoagulated non-AF patients.

The research was presented at Heart Rhythm 2016, the Heart Rhythm Society’s 37th Annual Scientific Sessions, May 4-7 in San Francisco .

AF is the most common sustained cardiac arrhythmia, with incidence rates that are growing dramatically with population aging.i, ii Many other chronic disorders of aging, such as dementia, are also increasing.

Dementia is a neurological disorder that impairs memory and other cognitive abilities, and it is now listed amongst the leading causes of morbidity and mortality in developed countries. AF can increase the risk of dementia because it exposes patients to both large and small clots that can affect brain function. Blood thinners used to prevent all forms of clots and strokes can increase the risk of both large and small brain bleeds that can also negatively impact brain function over time.

The study was conducted by the Intermountain Healthcare Clinical Pharmacist Anticoagulation Service, which is part of the Intermountain Healthcare system based in Salt Lake City. Researchers enrolled a total of 10,537 patients with no history of dementia prior to the study and who were treated with a blood thinner for AF and non-AF conditions like valvular heart disease and thromboembolism on a long-term basis. Other variables included age, hypertension, diabetes, hyperlipidemia, renal failure, smoking history, prior myocardial infarction or cerebral vascular accident, and heart failure. Participants were aged 18 years and older.

During a follow-up of approximately seven years, all types of dementia increased in the AF group more than the non-AF group. In both groups, however, the risk of dementia increased as the time in therapeutic range (TTR) decreased or became more erratic. When warfarin levels were consistently too high or too low, dementia rates increased regardless of why patients were receiving a blood thinner. However, regardless of the adequacy of anticoagulation, AF patients consistently experienced higher rates of all forms of dementia. This finding indicates that the efficacy of therapy is strongly associated with dementia. Of note, researchers found that patients younger than 70 years tended to be the most susceptible to the risk of dementia.

“Our study results are the first to show that there are significant cognitive risk factors for patients treated with warfarin over a long period of time regardless of the indication for anticoagulation,” said lead author T. Jared Bunch, M.D., director of heart rhythm research at Intermountain Medical Center Heart Institute and medical director for heart rhythm services for the Intermountain Healthcare system.

This study is important in many ways, Bunch said. “First, as physicians we have to understand that although we need to use anticoagulants for many reasons including to prevent stroke in AF patients, at that same time there are risks that need to be considered some of which we are only right now beginning to understand. In this regard, only those that absolutely need blood thinners should be placed on them long-term,” he added. “Second, other medications like aspirin that may increase the blood thinners effect should be avoided unless there is a specific medical need. Finally, in people that are on warfarin in which the levels are erratic or difficult to control, switching to newer agents that are more predictable may lower risk.”

In further exploring the association between AF, anticoagulation and dementia, this study offers insight into future treatment for patients with AF and for those taking a blood thinner for other needs. With AF raising the risk of dementia in addition to and independent of anticoagulation, how the abnormal rhythm is treated may be a way to lower dementia risk.

For more information: www.hrsonline.org

Related Content

Xarelto Reduces Ischemic Stroke for Coronary and Peripheral Artery Disease Patients
News | Antiplatelet and Anticoagulation Therapies | February 19, 2018
A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International Stroke Conference (ISC...
Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018
Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet...
Baxter Announces FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
Technology | Antiplatelet and Anticoagulation Therapies | January 22, 2018
January 22, 2018 — Baxter International Inc. announced the U.S.
News | Antiplatelet and Anticoagulation Therapies | January 19, 2018
The U.S. Food and Drug Administration (FDA) announced that International Laboratories LLC is voluntarily recalling Lot...
New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies | December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
News | Antiplatelet and Anticoagulation Therapies | November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies | November 06, 2017
November 6, 2017 —  The first trial to evaluate the safety of...
Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies | November 03, 2017
November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies | September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies | August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Overlay Init